Michael O'Dwyer to Protein Kinase Inhibitors
This is a "connection" page, showing publications Michael O'Dwyer has written about Protein Kinase Inhibitors.
Connection Strength
0.281
-
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807.
Score: 0.145
-
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. Br J Haematol. 2018 09; 182(5):654-669.
Score: 0.136